The Potential of CAR T Cell Therapy in Pancreatic Cancer.
The Potential of CAR T Cell Therapy in Pancreatic Cancer.
复制标题
DOI：
10.3389/fimmu.2018.02166
复制
发表时间：
2018
影响因子：
7.3
通讯作者：
Lesinski GB
中科院分区：
文献类型：
--
作者：
Akce M;Zaidi MY;Waller EK;El-Rayes BF;Lesinski GB
胰腺癌的预后很差，有效的治疗选择有限。预计到2030年，它将成为美国癌症相关死亡的第二大常见原因，对新的系统治疗方案的迫切需求尚未得到满足。针对PD-1、PD-L1、CTLA-4的抗体免疫治疗在非选择性胰腺癌中尚未显示出临床活性，强调了联合免疫治疗方法或其他治疗策略的必要性。因此，嵌合抗原受体(CAR)T细胞疗法代表了一种新兴的胰腺癌治疗选择。这种方法利用基因工程T细胞，这些T细胞被重定向到特定的癌症相关抗原，以诱导强大的细胞毒活性。这篇综述总结了可用的临床前数据，并重点介绍了使用CAR T细胞方法治疗胰腺癌的早期临床试验，胰腺癌是一种正在受到关注的疾病状态，作为细胞治疗的渠道。未来CAR T细胞治疗的应用方向也被考虑，包括其针对新表位的能力以及与其他治疗方案的结合。
Pancreatic cancer has a dismal prognosis and effective treatment options are limited. It is projected to be the second most common cause of cancer related mortality in the United States by 2030 and there is urgent unmet need for novel systemic treatment options. Immunotherapy with antibodies targeting PD-1, PD-L1, CTLA-4 has not shown clinical activity in unselected pancreatic cancer, emphasizing the need for combination immunotherapy approaches or other therapeutic strategies. As such, chimeric antigen receptor (CAR) T cell therapy represents an emerging therapeutic option for pancreatic cancer. This modality utilizes genetically engineered T cells that are redirected to specific cancer-associated antigens to elicit potent cytotoxic activity. This review summarizes the available preclinical data and highlights early phase clinical trials using CAR T cell approaches in pancreatic cancer, a disease state that is gaining attention as a conduit for cell therapy. Future directions in application of CAR T cell therapy are also considered including its ability to be directed against novel epitopes and combined with other therapeutic regimens.
登录
查看更多内容
影响因子：
11.4
作者：
Cooper ML;Choi J;Staser K;Ritchey JK;Devenport JM;Eckardt K;Rettig MP;Wang B;Eissenberg LG;Ghobadi A;Gehrs LN;Prior JL;Achilefu S;Miller CA;Fronick CC;O'Neal J;Gao F;Weinstock DM;Gutierrez A;Fulton RS;DiPersio JF
通讯作者：
DiPersio JF
影响因子：
82.9
作者：
Giavridis T;van der Stegen SJC;Eyquem J;Hamieh M;Piersigilli A;Sadelain M
通讯作者：
Sadelain M
影响因子：
10.1
作者：
Frigault MJ;Lee J;Basil MC;Carpenito C;Motohashi S;Scholler J;Kawalekar OU;Guedan S;McGettigan SE;Posey AD Jr;Ang S;Cooper LJ;Platt JM;Johnson FB;Paulos CM;Zhao Y;Kalos M;Milone MC;June CH
通讯作者：
June CH
设计的嵌合抗原受体T细胞用于治疗胰腺导管腺癌。
影响因子：
7.2
作者：
Beatty GL
通讯作者：
Beatty GL
影响因子：
29.4
作者：
Beatty GL;O'Hara MH;Lacey SF;Torigian DA;Nazimuddin F;Chen F;Kulikovskaya IM;Soulen MC;McGarvey M;Nelson AM;Gladney WL;Levine BL;Melenhorst JJ;Plesa G;June CH
通讯作者：
June CH